dc.contributor.author | Du, Y | |
dc.contributor.author | Carrio, I | |
dc.contributor.author | De Vincentis, G | |
dc.contributor.author | Fanti, S | |
dc.contributor.author | Ilhan, H | |
dc.contributor.author | Mommsen, C | |
dc.contributor.author | Nitzsche, E | |
dc.contributor.author | Sundram, F | |
dc.contributor.author | Vogel, W | |
dc.contributor.author | Oyen, W | |
dc.contributor.author | Lewington, V | |
dc.date.accessioned | 2017-07-05T11:10:57Z | |
dc.date.issued | 2017-09 | |
dc.identifier.citation | European journal of nuclear medicine and molecular imaging, 2017, 44 (10), pp. 1671 - 1678 | |
dc.identifier.issn | 1619-7070 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/685 | |
dc.identifier.eissn | 1619-7089 | |
dc.identifier.doi | 10.1007/s00259-017-3756-7 | |
dc.description.abstract | Purpose Radium Ra 223 dichloride (radium-223, Xofigo®) is the first targeted alpha therapy for patients with castration-resistant prostate cancer and symptomatic bone metastases. Radium-223 provides a new treatment option for this setting, but also necessitates a new treatment management approach. We provide straightforward and practical recommendations for European nuclear medicine centres to optimize radium-223 service provision.Methods An independent research consultancy agency observed radium-223 procedures and conducted interviews with all key staff members involved in radium-223 treatment delivery in 11 nuclear medicine centres across six countries (Germany, Italy, the Netherlands, Spain, Switzerland and the UK) experienced in administering radium-223. The findings were collated and discussed at a meeting of experts from these centres, during which key consensus recommendations were defined.Results The recommendations cover centre organization and preparation; patient referral; radium-223 ordering, preparation and disposal; radium-223 treatment delivery/administration; and patient experience. Guidance includes structured coordination and communication within centres and multidisciplinary teams, focusing on sharing best practice to provide high-quality, patient-centred care throughout the treatment pathway.Conclusions These expert recommendations are intended to complement existing management guidelines. Sharing best practice and experience will help nuclear medicine centres to optimize radium-223 service provision and improve patient care. | |
dc.format | Print-Electronic | |
dc.format.extent | 1671 - 1678 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Humans | |
dc.subject | Neoplasm Metastasis | |
dc.subject | Radium | |
dc.subject | Patient Selection | |
dc.subject | Expert Testimony | |
dc.subject | Patient Satisfaction | |
dc.subject | Male | |
dc.subject | Prostatic Neoplasms, Castration-Resistant | |
dc.title | Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2017-06-07 | |
rioxxterms.versionofrecord | 10.1007/s00259-017-3756-7 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2017-09 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | European journal of nuclear medicine and molecular imaging | |
pubs.issue | 10 | |
pubs.notes | No embargo | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Molecular Imaging | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Molecular Imaging | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 44 | en_US |
pubs.embargo.terms | No embargo | |
icr.researchteam | Translational Molecular Imaging | en_US |
dc.contributor.icrauthor | Oyen, Willem | |
dc.contributor.icrauthor | Marsden, | |